|1.||Kirkwood, John M: 7 articles (11/2014 - 01/2004)|
|2.||Hauschild, Axel: 6 articles (12/2015 - 08/2003)|
|3.||Gogas, Helen: 4 articles (12/2015 - 05/2004)|
|4.||Weichenthal, Michael: 4 articles (12/2015 - 08/2003)|
|5.||Atkins, Michael B: 4 articles (11/2014 - 01/2005)|
|6.||Zeuzem, Stefan: 4 articles (09/2012 - 07/2003)|
|7.||Eggermont, Alexander M M: 4 articles (05/2010 - 10/2005)|
|8.||Suciu, Stefan: 4 articles (05/2010 - 10/2005)|
|9.||Dieterich, Douglas T: 4 articles (12/2008 - 02/2004)|
|10.||Schäfer, Arne: 4 articles (04/2007 - 06/2003)|
|1.||Chronic Hepatitis C
01/01/1993 - "Efficacy of different regimens of interferon alfa-2b treatment in chronic hepatitis C."
11/01/2000 - "A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype."
01/01/2000 - "The aim of this study was to evaluate the most appropriate therapeutic protocol for patients with chronic hepatitis C not responding to a previous course of recombinant interferon alpha-2b (rIFN). "
07/01/1998 - "Seventy patients with chronic hepatitis C who participated in two trials of recombinant interferon alpha 2b treatment were studied. "
09/01/1997 - "We performed an independent meta-analysis of all available randomized clinical trials of interferon alfa-2b in patients with chronic hepatitis C. "
|2.||Melanoma (Melanoma, Malignant)
02/22/2001 - "The best results of adjuvant treatment in high-risk resected melanoma were published in 1996 by Kirkwood, who used interferon-alfa 2b. "
06/01/1999 - "In patients with stage IIb and III melanoma, the best results have been obtained with high doses of interferon alfa-2b, although toxicity is of concern. "
02/01/2001 - "Although trials of adjuvant interferon alfa-2b (IFN alpha-2b) in high-risk melanoma patients suggest improvement in disease-free survival, it is unclear whether treatment offers improvement in overall survival. "
07/01/2012 - "Enhanced anti-melanoma efficacy of interferon alfa-2b via inhibition of Shp2."
08/01/1998 - "Adjuvant therapy with interferon alfa-2b holds promise for patients with metastatic melanoma. "
09/01/1993 - "Concurrent with the cloning and development of the anti-HCV screening tests, trials with interferon alfa-2b have documented biochemical and histologic improvement in the indices of hepatitis C and non-A, non-B (NANB) in patients who were chronically infected. "
11/01/1994 - "To evaluate the efficacy of recombinant interferon alpha-2b in the treatment of patients with acute post-transfusion hepatitis C, a randomized controlled trial was conducted in 33 acute post-transfusion hepatitis C patients; 16 patients received 3 million units of subcutaneously injected recombinant interferon alpha-2b 3 times a week for 3 months and 17 patients without specific treatment were used as controls. "
01/01/2002 - "Four trials assessing interferon alfa-2b in 141 patients, all with transfusion-acquired acute hepatitis C, were included. "
09/01/1997 - "Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials."
12/01/2007 - "We report the successful use of electroconvulsive therapy in a patient who developed major depression with psychotic features while being treated with interferon alfa-2b for hepatitis C. "
|4.||Chronic Hepatitis B
01/01/1990 - "Our data indicate that small doses of recombinant interferon alfa-2b given during a 12-week period induce a significant reduction in viral replication and approximately triple the spontaneous seroconversion rate observed in patients with chronic hepatitis B."
08/02/1990 - "In chronic hepatitis B, treatment with interferon alfa-2b (5 million units per day for 16 weeks) was effective in inducing a sustained loss of viral replication and achieving remission, assessed biochemically and histologically, in over a third of patients. "
04/01/2005 - "Safety and efficacy of an indigenous human recombinant interferon alpha 2b (Shanferon) in patients with chronic hepatitis B."
01/01/1993 - "This paper reviews the results of recent studies carried out in the USA on the treatment of chronic hepatitis B with interferon alfa-2b. "
05/01/2002 - "[Interferon alfa 2b treatment decreases histological activity in children with chronic hepatitis B]."
01/01/1987 - "Both in vitro and in vivo studies have demonstrated antiproliferative effects of interferon alfa-2b (Intron A; Schering-Plough) when tested with human tumor cells. "
02/01/2012 - "According to American Joint Committee on Cancer classification, complete control with topical interferon alfa-2b can be achieved in 67% of Tis, 85% of T3, and 83% of all OSSN."
02/01/2012 - "Complete tumor resolution was achieved in 19 tumors (83%) following topical interferon alfa-2b treatment for a median period of 6 months (mean, 7 months; range, 1-12 months) and maintained for up to 24 months of follow-up. "
02/01/2012 - "Clinically visible OSSN in 20 patients (23 tumors) was managed with topical interferon alfa-2b, 1 million IU/mL, 4 times daily. "
02/01/2012 - "Topical interferon alfa-2b for management of ocular surface squamous neoplasia in 23 cases: outcomes based on American Joint Committee on Cancer classification."
|5.||peginterferon alfa-2b (Pegintron)
|6.||Hepatitis B e Antigens
|7.||Interferon Alfa-2a (Interferon Alfa 2a)
|10.||Interferon-alpha (Interferon Alfa)
|2.||Drug Therapy (Chemotherapy)